Alnylam Pharmaceuticals would contribute over 1,500 RNA interference (RNAi) patents to the patent pool established by GlaxoSmithKline in March 2009. Alnylam is known for the development of therapeutics based on RNAi for the treatment of respiratory syncytial virus (RSV) infection, liver cancer, hypercholesterolemia, Huntington’s disease, and TTR amyloidosis. The patents in the pool will be provided on a royalty-free, non-profit basis in Least Developed Countries via licensing agreements with qualified third parties.